• 1. Enabling high-throughput single-animal gene-expression studies with molecular and micro-scale technologies
  Jason Wan Lab Chip, 2020,20, 4528-4538
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 5. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Benzisoxazoles
• Solvents and Organic Chemicals Organic Compounds Amines/Sulfonamides

Professional Introduction to 7-Bromobenzodisoxazol-3-amine (CAS No. 1260860-32-9)

7-Bromobenzodisoxazol-3-amine, a compound with the chemical identifier CAS No. 1260860-32-9, represents a significant advancement in the field of pharmaceutical chemistry. This heterocyclic amine has garnered considerable attention due to its unique structural properties and potential applications in drug development. The presence of both bromine and amine functional groups makes it a versatile intermediate for synthesizing complex molecules, particularly in the realm of medicinal chemistry.

The benzodisoxazole core of 7-Bromobenzodisoxazol-3-amine is known for its stability and reactivity, which are highly valued in the design of bioactive compounds. This structural motif has been extensively studied for its role in modulating various biological pathways, including those involved in inflammation, pain perception, and neurological disorders. Recent research has highlighted its potential as a scaffold for developing novel therapeutic agents that target specific disease mechanisms.

In the context of modern drug discovery, the bromine substituent in 7-Bromobenzodisoxazol-3-amine plays a crucial role in facilitating further chemical modifications. This allows researchers to introduce additional functional groups or linkages, enabling the creation of highly customized molecules with tailored pharmacological properties. The amine group, on the other hand, provides a nucleophilic site that can engage in various chemical reactions, such as condensation or substitution, further expanding the synthetic possibilities.

One of the most compelling aspects of 7-Bromobenzodisoxazol-3-amine is its utility in the synthesis of kinase inhibitors. Kinases are enzymes that play a pivotal role in cell signaling pathways, and their dysregulation is often associated with cancer and other chronic diseases. By designing molecules that selectively inhibit specific kinases, researchers can develop treatments that precisely target disease-causing pathways without affecting healthy cells. The benzodisoxazole scaffold has been shown to be particularly effective in this regard, offering a stable platform for kinase inhibition.

Recent studies have demonstrated the efficacy of derivatives of 7-Bromobenzodisoxazol-3-amine in preclinical models of cancer. For instance, researchers have synthesized analogs that exhibit potent inhibitory activity against tyrosine kinases, which are overexpressed in many tumor types. These findings suggest that further optimization of the compound could lead to the development of novel anticancer drugs with improved selectivity and reduced side effects. The bromine atom in these derivatives has been particularly useful in enhancing binding affinity to target proteins, thereby increasing their therapeutic potential.

The pharmaceutical industry has also explored the use of 7-Bromobenzodisoxazol-3-amine as a building block for nonsteroidal anti-inflammatory drugs (NSAIDs). NSAIDs are widely used to alleviate pain and reduce inflammation by inhibiting cyclooxygenase (COX) enzymes. The benzodisoxazole core has been found to interact favorably with COX enzymes, suggesting its potential as a lead compound for developing new NSAIDs with enhanced efficacy and reduced gastrointestinal toxicity.

In addition to its applications in oncology and anti-inflammatory therapy, 7-Bromobenzodisoxazol-3-amine has shown promise in treating neurological disorders. Emerging research indicates that benzodisoxazole derivatives can modulate neurotransmitter activity by interacting with specific receptors or ion channels in the brain. This opens up new avenues for developing treatments for conditions such as epilepsy, depression, and neurodegenerative diseases. The ability to fine-tune the pharmacological properties of these compounds through structural modifications makes them particularly attractive for therapeutic development.

The synthesis of CAS No. 1260860-32-9, 7-Bromobenzodisoxazol-3-amine, involves multi-step organic reactions that highlight the compound's synthetic versatility. Starting from readily available precursors, researchers can employ a series of bromination and condensation reactions to construct the benzodisoxazole core. The introduction of the amine group is typically achieved through nucleophilic substitution or reduction reactions, depending on the desired regioselectivity.

The purity and yield of these synthetic routes are critical factors that influence their industrial applicability. Advanced purification techniques such as column chromatography and recrystallization are often employed to ensure high-quality intermediates and final products. These methods not only enhance the efficiency of drug production but also minimize impurities that could potentially affect biological activity or safety.

The growing interest in green chemistry principles has also influenced the synthesis of CAS No. 1260860-32-9. Researchers are increasingly adopting solvent-free reactions, catalytic methods, and biocatalysis to reduce environmental impact while maintaining high yields and selectivity. Such sustainable approaches align with global efforts to promote environmentally responsible chemical manufacturing practices.

In conclusion, 7-Bromobenzodisoxazol-3-amine (CAS No. 1260860-32-9) represents a valuable asset in pharmaceutical research due to its structural versatility and potential therapeutic applications. Its role as an intermediate for synthesizing kinase inhibitors, NSAIDs, and neuroactive compounds underscores its importance in drug discovery efforts worldwide. As research continues to uncover new applications for this compound, it is likely to remain at the forefront of medicinal chemistry innovation.

• 36216-80-5(1,2-benzoxazol-3-amine)
• 1935006-84-0(5-Bromo-N,N-dimethylbenzo[d]isoxazol-3-amine)
• 89583-81-3(5,7-Dibromobenzo[d]isoxazol-3-amine)
• 1404480-14-3(5-Bromo-N-methylbenzo[d]isoxazol-3-amine)
• 455280-00-9(5-Bromobenzodisoxazol-3-ylamine)
• 915301-12-1(1,2-BENZISOXAZOL-3-AMINE, 6-BROMO-, HYDROCHLORIDE (1:1))
• 1260751-81-2(7-bromo-1,2-benzisoxazole)
• 796969-15-8(4-BromobenzoDisoxazol-3-amine)
• 2386775-62-6(1,2-Benzisoxazol-3-amine, 6-bromo-N,N-dimethyl-)
• 177995-39-0(6-bromo-1,2-benzoxazol-3-amine)